Compare LGI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGI | IMUX |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.3M | 209.2M |
| IPO Year | N/A | 2013 |
| Metric | LGI | IMUX |
|---|---|---|
| Price | $18.70 | $14.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 32.5K | ★ 182.6K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.32 | $0.51 |
| 52 Week High | $19.88 | $15.84 |
| Indicator | LGI | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 58.08 |
| Support Level | $18.69 | $0.74 |
| Resistance Level | $19.30 | $15.81 |
| Average True Range (ATR) | 0.22 | 0.90 |
| MACD | 0.05 | -0.17 |
| Stochastic Oscillator | 76.67 | 40.69 |
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.